For many families, Alzheimer’s disease begins with small changes that are easy to overlook.
A person may forget appointments, struggle to find the right words, or become confused about familiar tasks. Over time, these symptoms often worsen as the disease gradually damages the brain.
Because Alzheimer’s develops slowly, doctors have long searched for ways to identify it earlier and measure how far it has progressed.
Early diagnosis can help patients receive treatment sooner, participate in clinical trials, and make important decisions about future care. Unfortunately, the tests currently used to confirm Alzheimer’s are not always easy to access.
Brain imaging scans can cost thousands of dollars and may not be available in every hospital or clinic. Another option, known as a spinal tap, involves collecting fluid from around the spinal cord. While generally safe, many patients find the procedure intimidating or uncomfortable.
A new study offers hope that a much simpler approach may soon be possible. Researchers have developed a blood test model that could help doctors track Alzheimer’s disease using only a small blood sample.
The key to the test lies in a protein called tau. Scientists have known for many years that abnormal tau proteins accumulate in the brains of people with Alzheimer’s disease. These protein changes are closely linked to the loss of brain cells and the progression of symptoms.
In the new study, researchers focused on two specific forms of tau that can be detected in the bloodstream. By measuring these proteins, they created a model designed to estimate the stage of Alzheimer’s disease.
To evaluate the model, the team analyzed data from more than 1,000 individuals. The participants included healthy adults with normal thinking abilities, people with mild cognitive impairment, patients with Alzheimer’s dementia, and individuals diagnosed with other neurological diseases.
The researchers compared the blood test results with findings from PET scans. PET scans are considered one of the most reliable methods for examining Alzheimer’s-related changes inside the brain. They allow doctors to see the buildup of abnormal proteins that characterize the disease.
The comparison showed that the blood-based model performed remarkably well. The staging information generated by the blood test closely matched the staging obtained through PET imaging. This suggests that the test may provide valuable information about disease progression without requiring advanced imaging technology.
If future studies confirm these findings, the impact could be substantial. A simple blood test could be performed in many medical settings, including clinics that do not have access to specialized imaging equipment. This could make Alzheimer’s testing available to far more people than it is today.
Experts believe that easier testing could also accelerate research. Clinical trials often require participants to undergo expensive scans before enrollment. Blood-based screening could simplify this process and help researchers identify suitable candidates more efficiently.
Dr. Randy D’Amico, who reviewed the findings but was not involved in the study, said the technology could dramatically improve access to biological testing for Alzheimer’s disease. He also emphasized that better disease staging could help doctors match patients with appropriate treatments and potentially improve outcomes.
The possibility of preventing or delaying irreversible brain damage is especially exciting. Many newer Alzheimer’s therapies appear to work best when used early in the disease process. A widely available blood test could help identify patients during these earlier stages.
Despite the encouraging results, important questions remain. Researchers must determine how consistently the test performs across different populations and healthcare systems. Larger studies will also be needed before the test can become part of routine medical practice.
If you care about Alzheimer’s disease, please read studies about vitamin D deficiency linked to Alzheimer’s and dementia, and strawberries can be good defence against Alzheimer’s.
For more health information, please see recent studies about foods that reduce Alzheimer’s risk, and oral cannabis extract may help reduce Alzheimer’s symptoms.
The study was published in JAMA Neurology.
Source: JAMA Neurology study researchers.
